Nasal fluid sample containing Aβ, pTau, and / or tTau

Nasal fluid samples, collected near the olfactory cleft, offer a non-invasive alternative to CSF analysis by replicating marker protein patterns and concentrations, facilitating reliable diagnosis of neurodegenerative diseases.

JP2026520363APending Publication Date: 2026-06-23NOSELAB GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
NOSELAB GMBH
Filing Date
2024-05-10
Publication Date
2026-06-23

AI Technical Summary

Technical Problem

Current methods for diagnosing neurodegenerative diseases, such as Alzheimer's and Parkinson's, rely on cerebrospinal fluid (CSF) analysis, which is invasive and costly, and nasal fluid samples have shown inconsistent and low concentrations of marker proteins, making them unreliable for diagnostic patterns.

Method used

Collecting nasal fluid samples near the olfactory cleft using an absorbent matrix device to obtain samples with marker proteins like Aβ, pTau, and tTau, demonstrating equivalent patterns and concentrations to CSF samples, allowing for reliable diagnostic evaluation.

Benefits of technology

Nasal fluid samples provide nearly identical marker protein signatures and correlations as CSF, enabling accurate diagnosis of neurodegenerative diseases by quantifying these proteins, validating results, and identifying disease patterns.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026520363000001_ABST
    Figure 2026520363000001_ABST
Patent Text Reader

Abstract

The present invention relates to a nasal fluid sample obtained from a subject containing marker proteins (multiple) such as β-amyloid (Aβ), phosphorylated tau (pTau), and / or total tau (tTau). The present invention further relates to a nasal fluid sample containing marker proteins (multiple) such as Aβ, pTau, and / or tTau for use in a method for aiding the diagnosis of neurodegenerative diseases, and to the use of a nasal fluid sample containing marker proteins (multiple) such as Aβ, pTau, and / or tTau for aiding the diagnosis of neurodegenerative diseases. The present invention further relates to a method for aiding the diagnosis of neurodegenerative diseases in a subject / individual.
Need to check novelty before this filing date? Find Prior Art